Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group
- 29 December 2015
- journal article
- review article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 30 (5), 1005-1017
- https://doi.org/10.1038/leu.2015.356
Abstract
No abstract availableKeywords
This publication has 127 references indexed in Scilit:
- Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II studyBlood Cancer Journal, 2013
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group studyLeukemia, 2011
- Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Multiple MyelomaTransplantation and Cellular Therapy, 2010
- A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myelomaAnnals of Hematology, 2010
- Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trialThe Lancet Oncology, 2009
- Second auto-SCT is safe and effective salvage therapy for relapsed multiple myelomaBone Marrow Transplantation, 2008
- Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple MyelomaNew England Journal of Medicine, 2007
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- Single versus Double Autologous Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2003
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999